Prestige Biologics Co., Ltd. (KOSDAQ:334970)

South Korea · Delayed Price · Currency is KRW

1,166.00

-65.00 (-5.28%)

At close: Oct 28, 2026

Prestige Biologics Financials Overview

Financials in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022
Revenue	26,665	26,665	12,533	2,169	1,746	15.57
Revenue Growth	112.76%	112.76%	477.82%	24.24%	11115.88%	-99.52%
Gross Profit	-19,417	-19,417	-15,984	-8,844	493.75	-8.71
Operating Income	-49,302	-49,302	-33,682	-33,430	-40,043	-36,631
Net Income	-51,220	-51,220	-27,469	-29,374	-39,442	-49,718
Earnings Per Share	-658.76	-658.76	-373.00	-480.00	-672.37	-960.73
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2024	FY 2023
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023
Antibody Drugs	1,479	3,164
Other than Service	689.62	296.77

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022
Cash & Investments	6,943	6,943	1,582	29,507	45,435	15,383
Total Debt	101,306	101,306	91,461	173,043	160,016	118,619
Net Cash (Debt)	-94,364	-94,364	-89,879	-143,536	-114,581	-103,236
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-1213.64	-1213.64	-1220.44	-2345.53	-1953.28	-1994.89

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022
Operating Cash Flow	3,203	3,203	-18,308	-8,345	-24,830	-34,124
Capital Expenditures	-2,292	-2,292	-5,226	-8,522	-35,435	-84,642
Free Cash Flow	910.95	910.95	-23,534	-16,867	-60,265	-118,767
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022
Gross Margin	-72.82%	-72.82%	-127.53%	-	28.28%	-55.97%
Operating Margin	-184.89%	-184.89%	-268.74%	-1541.23%	-2293.61%	-235333.31%
Pretax Margin	-192.09%	-192.09%	-219.17%	-1354.23%	-2259.19%	-319407.01%
Profit Margin	-192.09%	-192.09%	-219.17%	-1354.23%	-2259.19%	-319407.01%
FCF Margin	3.42%	3.42%	-187.77%	-777.63%	-3451.94%	-763002.69%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 29, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022
P/FCF Ratio	99.52	189.49	-	-	-	-
PS Ratio	3.40	6.47	22.64	113.13	156.11	11855.95